John Vavricka - Jan 31, 2024 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
Chief Commercial Officer
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka
Stock symbol
AVIR
Transactions as of
Jan 31, 2024
Transactions value $
-$45,420
Form type
4
Date filed
2/2/2024, 09:25 PM
Previous filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVIR Common Stock Options Exercise +33.3K 33.3K Jan 31, 2024 Direct F1
transaction AVIR Common Stock Sale -$45.4K -11.8K -35.46% $3.84 21.5K Feb 1, 2024 Direct F2
holding AVIR Common Stock 82.5K Jan 31, 2024 Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Restricted Stock Units Options Exercise $0 -33.3K -33.33% $0.00 66.7K Jan 31, 2024 Common Stock 33.3K Direct F1, F3
transaction AVIR Stock Option (Right to Buy) Award $0 +133K $0.00 133K Jan 31, 2024 Common Stock 133K $4.16 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 25, 2022.
F3 The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
F4 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.